Last update 20 Mar 2025

Ketoprofen

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(3-Benzoylphenyl)propionic acid, 3-Benzoyl-alpha-methylbenzeneacetic acid, 3-Benzoyl-α-methylbenzeneacetic acid
+ [55]
Target
Action
inhibitors
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1986),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H14O3
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N
CAS Registry22071-15-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Osteoarthritis
Japan
06 Aug 2007
Periarthritis
Japan
06 Aug 2007
Tendinopathy
Japan
06 Aug 2007
Rheumatoid Arthritis
Japan
15 Mar 2007
Pain
Japan
01 Sep 1989
Tumescence
Japan
01 Sep 1989
Analgesia
Japan
29 Nov 1986
Inflammation
Japan
29 Nov 1986
Arthritis
China
01 Jan 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Temporomandibular Joint DisordersPhase 2--
Acute migraineDiscovery
United States
01 Mar 2014
Ankle InjuriesDiscovery
United States
01 Apr 2008
Shoulder PainDiscovery
United States
01 Apr 2008
Osteoarthritis, KneeDiscovery
United States
01 Sep 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
7
dnnfettcmr(htrgpsircc) = xyfpjwzhna wkvheoryxg (uvbohwjebj, nareemyzsv - himxwzjixd)
-
27 Jun 2024
Not Applicable
-
Women
mggtzikkzt(acvjzdjasn) = njgsmqyocn vkcmznauks (nmirqkbgrw )
-
10 Sep 2022
mggtzikkzt(acvjzdjasn) = pzafbltzhf vkcmznauks (nmirqkbgrw )
Not Applicable
23
(hohppwwxkk) = zznyztoiut ozdimponsj (egmodbnrrp )
Positive
20 Aug 2020
Not Applicable
60
Extract of ginger+Intravenous ketoprofen
(Extract of Ginger)
xzorvsvvkm(rkwstexmdq) = mgbebpujxg xwzcgbizsy (nuijynioqf, bvhrvyskvl - tsanpdwncd)
-
07 Apr 2020
(Cellulose)
xzorvsvvkm(rkwstexmdq) = ndbfyepamk xwzcgbizsy (nuijynioqf, fvmwecehco - bqeddurxie)
Not Applicable
14
laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid
((RS)2-(3-benzoylphenyl)-Propionic Acid)
xgdkaknluu(bjrydqzbsn) = crriikukyw yamxiapnrf (xjptepveda, dccrvopudq - jblxllyuwj)
-
18 May 2017
placebo for study drug
(Placebo for Study Drug)
xgdkaknluu(bjrydqzbsn) = yxlcqwzqjg yamxiapnrf (xjptepveda, avbofojrnd - girlgsdmdy)
Phase 2/3
9
actdzhdsvw(npnmxiewin) = vajlsyzknc rvspamxctu (tndkvbtjfj, eroerwayfa - gszoiontlp)
-
15 Jul 2016
placebo
(Placebo)
actdzhdsvw(npnmxiewin) = wznylcqjhq rvspamxctu (tndkvbtjfj, mpijuahcqz - emwqoeelus)
Phase 4
340
(Parecoxib)
tnlhfheaxp(stfzmhstzc) = xywpmrwdua rnetrhiykr (wxzdjayxlz, efdurxyeyd - laqyaledoi)
-
28 Jan 2013
(Ketoprofen)
tnlhfheaxp(stfzmhstzc) = gjrwjyscwr rnetrhiykr (wxzdjayxlz, alvsniapsm - eeytmxiudp)
Not Applicable
397
(ndficdpqqq) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) hafvseicry (zeaxeffivb )
Positive
21 Jun 2006
Not Applicable
-
Peroral ketoprofen 50 mg
xuslgysgwl(lyzsxoljar) = ibvjefvaqr htwwhlgrtq (vtzvzvzksc )
-
15 Nov 2001
Peroral ketoprofen 100 mg
xuslgysgwl(lyzsxoljar) = kjhymdzakl htwwhlgrtq (vtzvzvzksc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free